ClinicalTrials.Veeva

Menu

SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER

Pfizer logo

Pfizer

Status

Begins enrollment in 1 month

Conditions

Respiratory Syncytial Virus Infection

Treatments

Biological: RSVpreF vaccine

Study type

Observational

Funder types

Industry

Identifiers

NCT06546800
C3671019

Details and patient eligibility

About

This post-marketing study is a multicenter cohort study in individuals aged 60 years or older vaccinated with Abrysvo (RSV vaccine)designed to confirm the safety in individuals aged 60 years or older under actual clinical practice in Japan.

Enrollment

1,100 estimated patients

Sex

All

Ages

60+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Individuals aged 60 years or older who have been vaccinated with Abrysvo for the first time after Abrysvo is launched. Those who have previously participated in the clinical trials of this product will be excluded.
  2. Vaccinated participants (or his/her legally acceptable representative) who understand the information on this study and have provided written consent regarding their participation in the study.

Exclusion criteria

-There are no exclusion criteria for this study.

Trial design

1,100 participants in 1 patient group

RSVpreF vaccine
Description:
Individuals aged 60 years or older who has been vaccinated with Abrysvo for the first time.
Treatment:
Biological: RSVpreF vaccine

Trial contacts and locations

1

Loading...

Central trial contact

Pfizer CT.gov Call Center

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems